BofA analyst Charlie Yang initiated coverage of CG Oncology with a Buy rating and $65 price target. CG is a clinical stage biotech developing a next-generation immunotherapy to treat bladder cancer, the analyst tells investors in a research note. The firm thinks the company’s cretostimogene “can fill the void” and transform the non-muscle invasive bladder cancer treatment paradigm with superior efficacy and durability versus existing therapies.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CGON:
- CG Oncology initiates EAP for Cretostimogene Grenadenorepvec in U.S.
- CG Oncology Initiates Expanded Access Program for Cretostimogene Grenadenorepvec
- CG Oncology Announces Nature Medicine Publication of Final Results from CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in BCG-Unresponsive NMIBC
- CG Oncology to Present Positive Final Results from Phase 2 CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in BCG-Unresponsive High-Risk NMIBC at ASCO 2024 Annual Meeting
- CG Oncology upgraded to Buy from Neutral at Goldman Sachs